View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 5, 2021updated 19 Jan 2022 5:42pm

Natera’s MRD test shows clinical utility in colorectal cancer

Signatera is intended to monitor treatment and analyse molecular residual disease in cancer-diagnosed patients.

Natera has reported the latest data from the CIRCULATE trial, which expands the clinical utility of its tailored and tumour-informed molecular residual disease (MRD) assay, Signatera, in colorectal cancer (CRC).

A circulating tumour DNA (ctDNA) test, Signatera is used for monitoring of treatment and molecular residual disease (MRD) analysis in cancer-diagnosed patients.

It offers each person a personalised blood test made to fit the unique signature of clonal mutations seen in that patient’s tumour.

This increases the accuracy of Signatera in identifying residual disease’s presence or absence from a blood sample, at levels of even one tumour molecule in a tube of blood.

Furthermore, the test is indicated for identifying and measuring the extent of cancer left in a patient’s body, to check for recurrence sooner and aid in enhancing treatment decisions.

Available for clinical and research use, the test obtained three breakthrough device designations from the US Food and Drug Administration (FDA) for various cancer types and indications.

The prospective, multi-centre randomised CIRCULATE-Japan trial assessed ctDNA-guided therapy strategies for stage I-IV resected CRC patients. It is considered the largest MRD-guided study in CRC so far.

The company noted that as follow-up data is available from the initial 808 subjects in the trial, it will become several times bigger than any earlier Natera MRD study in CRC and form a new benchmark for assessing the performance of the assay.

In the CIRCULATE-Japan trial, Signatera tests were used preoperatively and then serially following surgery. In 95% of stage II–III CRC subjects, preoperative MRD was identified.

Longitudinal MRD-positivity was substantially linked to inferior disease-free survival and Signatera showed a 93.1% relapse sensitivity.

Furthermore, a prospective study of seven pancreatic adenocarcinoma patients and one ampullary adenocarcinoma patient assessed use of Signatera after surgery.

Blood biomarkers carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9) and radiological imaging were also analysed.

MRD-positivity was noted to be linked to reduced recurrence-free survival while MRD findings were associated with and preceded imaging results in all patients who relapsed.

Natera medical affairs, oncology vice-president Alexey Aleshin said: “CIRCULATE-Japan is a landmark prospective trial and based on these strong interim results, we are highly optimistic they will lead to changes in practice guidelines in early-stage colorectal cancer.

“At our core, we are a data-driven company, and these data very clearly demonstrate that Signatera can be an important and accurate tool for helping patients avoid unnecessary treatment.”

The company presented the data at the 2021 European Society for Medical Oncology World Congress on Gastrointestinal Cancer held between 30 June and 3 July.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network